| Document |
Document Title |
|
WO/2024/059252A3 |
An ECM-embedded vascular channel-on-a-chip includes an outer case having an internal chamber, an ECM provided within the chamber, the ECM having a cross-sectionally rounded vascular channel having a first end and a second end opposite th...
|
|
WO/2024/036105A3 |
A method of generating cells of the T cell lineage is provided that involves culturing a sample comprising stem cells or progenitor cells with an engineered Notch ligand conjugated to a suspension support and isolating cells of the T cel...
|
|
WO/2024/059070A9 |
The invention provides a method of producing a population of CD34+ hematopoietic precursor cells. The CD34+ hematopoietic precursor cells are used in methods of producing natural killer (NK), methods of inducing NK cell differentiation f...
|
|
WO/2024/086825A2 |
Provided herein are compositions for a Herpes Simplex Virus packaging system and packaging cell line. Also provided herein are compositions, systems, and methods for producing a packaging cell line for Herpes Simplex Virus amplicons.
|
|
WO/2023/230598A3 |
Disclosed are methods of producing recombinant feline morbillivirus (FeMV) using reverse genetics. In some aspects, the methods comprise: (a) extracting FeMV RNA from an isolated FeMV positive sample, (b) generating cDNAs from the FeMV R...
|
|
WO/2024/085215A1 |
Although differentiating pluripotent stem cells by temporarily differentiating the pluripotent stem cells into CTraS considerably increases the subsequent cell differentiation efficiency, it is difficult to stably induce pluripotent stem...
|
|
WO/2024/085651A1 |
The present invention relates to a medium composition for inducing differentiation from stem cells to macrophages. The medium composition for inducing differentiation from stem cells to macrophages according to one aspect, can provide th...
|
|
WO/2024/084516A1 |
The present invention discloses a recombinant nucleic acid molecule encoded at least by an ORF (100, 100a) to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one hairpin loop structure...
|
|
WO/2024/085650A1 |
The present invention relates to a medium composition for inducing differentiation from a stem cell to a macrophage. According to a medium composition for inducing differentiation from a stem cell to a macrophage, according to one aspect...
|
|
WO/2024/084243A1 |
The invention relates to methods of non-cell autonomous modulation of reprogramming comprising providing a non-cell autonomous reprogramming factor which derives from a cell other than the somatic cell to be reprogrammed. The invention f...
|
|
WO/2024/084520A1 |
The present invention discloses a recombinant nucleic acid molecule encoded at least by an ORF (100, 100a) to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one first hairpin loop str...
|
|
WO/2024/050486A3 |
The disclosure provides for vaccine preparations compnsing isolated or purified extracellular blebs that display engineered MHC I and MHC II peptides that target specific antigen(s) or a specific epitope(s) from a pathogen, and uses ther...
|
|
WO/2024/059821A3 |
Compositions for the treatment of cancer that include CAR T cells in which expression of FOXO3 expression is silenced are disclosed in various aspects. In various other aspects, methods for preventing or delaying a development of dysfunc...
|
|
WO/2024/083745A1 |
The current invention relates to cell - cell interaction and in particular to cellular avidity. Provided are improved means and methods to study cell - cell interaction and characterizing cellular avidity. Highly advantageously, it was s...
|
|
WO/2024/086342A1 |
The present disclosure provides methods for generating and/or purifying secretomes, extracellular vesicles, and fractions thereof, from progenitor cells; and provides compositions containing such generated secretomes, extracellular vesic...
|
|
WO/2024/085449A1 |
The present invention relates to a method for producing microparticles. The method for producing microparticles can produce microparticles having a uniform size and a narrow density range. Therefore, the method for producing microparticl...
|
|
WO/2024/086190A1 |
The disclosure relates to chimeric antigen receptor (CAR) specific to CD 19, vectors encoding the same, and recombinant T cells comprising the CD 19 CAR. The disclosure also includes methods of administering a genetically modified T cell...
|
|
WO/2024/086521A1 |
The present disclosure relates to methods for inducing rejuvenation in a population of glial progenitor cells and methods for treating a subject having a glial cell-related disorder. Methods include administering, to the population of ad...
|
|
WO/2024/085081A1 |
Provided is an antibody that specifically binds to the extracellular domain of human LPA1 but does not specifically bind to the extracellular domain of human LPA2 or the extracellular domain of human LPA3. The antibody preferably has act...
|
|
WO/2024/082025A1 |
The present disclosure relates generally to T cells that are modified to enhance the efficiency of adoptive cell therapy (ACT) by enhancing T cell function (e.g., CAR-T cell effector function), without affecting persistence. The present ...
|
|
WO/2024/086695A2 |
Described herein are mouse models of porphyrias, including mouse models of X- linked protoporphyria and erythropoietic protoporphyria (EPP). Immortalized human CD34+ blood cell lines expressing shRNAs targeting a human Ferrochelatase (FE...
|
|
WO/2024/082269A1 |
Provided are an application of a bispecific antibody in immune cell therapy, and a method for improving immune cell killing activity.
|
|
WO/2024/084932A1 |
[Problem] To provide a new carrier peptide fragment having cell membrane permeability. [Solution] The carrier peptide fragment disclosed herein is introduced into at least the cytoplasm of a eukaryotic cell from outside the cell and comp...
|
|
WO/2024/085261A1 |
Provided are: a novel microparticle that includes miRNA for controlling the production of nitric oxide and that is an agent for promoting the production of nitric oxide, said microparticle being capable of controlling the expression of a...
|
|
WO/2024/085252A1 |
The purpose of the present invention is to provide a novel method of preparing a cell that has undergone blastogenesis. A system (100) for preparing a cell that has undergone blastogenesis comprises an irradiation means (1, 21) which irr...
|
|
WO/2024/086191A2 |
The disclosure relates to immune cells comprising one or more vectors comprising a nucleic acid sequence encoding a chimeric antigen receptor specific for CD 19 and a nucleic acid sequence encoding an enhancer of T cell priming (e.g., IL...
|
|
WO/2024/085165A1 |
The present disclosure provides a cell culture medium for culturing fish cells, a culture method for fish cells, and an oral vaccine for fish. In the present disclosure, the cell culture medium for culturing fish cells preferably contain...
|
|
WO/2024/082178A1 |
Provided is a chimeric antigen receptor, comprising a first antigen-binding domain and a second antigen-binding domain, wherein the first antigen-binding domain targets CD19, and the second antigen-binding domain targets CD22. Also provi...
|
|
WO/2024/086796A1 |
The present disclosure is generally directed to methods of using antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A,...
|
|
WO/2024/059776A3 |
Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells ...
|
|
WO/2024/085898A1 |
The present disclosure relates to systems, apparatuses, and methods for preparing cell-based meat products (i.e., comestible meat products). In particular, a pipe-based bioreactor is disclosed having one or more substrates disposed there...
|
|
WO/2024/083135A1 |
The disclosure provides IscB polypeptides for various applications, e.g., double-strand cleavage, base editing, prime editing.
|
|
WO/2024/083213A1 |
The present invention relates to a modified T cell, a preparation method therefor and a use thereof. The expression of endogenous TRAC, B2M and CD7 genes in the T cell is inhibited, and the T cell expresses a chimeric antigen receptor ta...
|
|
WO/2024/082383A1 |
The present invention provides an anti-human interleukin 36 receptor (IL-36R) monoclonal antibody and a use thereof. The monoclonal antibody comprises three heavy chain complementarity determining regions CDR-H1, CDR-H2 and CDR-H3 and th...
|
|
WO/2024/084519A1 |
The present invention discloses a recombinant nucleic acid molecule encoded at least by an ORF (100, 100a) to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one first hairpin loop str...
|
|
WO/2024/040061A3 |
We have discovered that allogeneic HSC-engineered human iNKT (3rdHSC-iNKT) cells display potent anti-GvHD functions, by eliminating antigen-presenting myeloid cells in vitro and in xenograft models, without negatively impacting tumor era...
|
|
WO/2024/085085A1 |
[Problem] To provide a method for producing a dendritic cell formulation that stimulates NKT cells, from monocytes collected from a recipient (monocytes collected by apheresis or peripheral blood containing monocytes), and that can exhib...
|
|
WO/2024/085763A1 |
The invention concerns an in vitro method for producing a 3D structure of endoderm cells, mesoderm cells and ectoderm cells and capable of further organogenesis to form an organ or organ-like cell structure. The method comprises seeding ...
|
|
WO/2024/082005A1 |
The present invention provides for chimeric antigen receptor constructs capable of being expressed in dendritic cells (DCs), and DCs modified to express one or more chimeric antigen receptors (CARs) as well as compositions comprising the...
|
|
WO/2024/084082A1 |
The present invention relates to pluripotent stem cell comprising an expression construct for expression of a PPAR-γ protein and an expression construct for expression of a CEBPαprotein. The invention further provides for methods of...
|
|
WO/2024/085315A1 |
According to a human fibroblast culture fluid complex (G4PRF-300) effective for regenerating human tissues, a preparation method therefor, and a topical liquid composition containing same, proposed in the present invention, 26 complex gr...
|
|
WO/2024/086456A1 |
The present invention relates to a method and apparatus for passive collection of sperm having improved motility from a semen sample. The semen sample is contacted with on side of a porous barrier and a nutrient-containing media is conta...
|
|
WO/2024/083097A1 |
Disclosed in the present invention is an IL-2 mutant, having at least one of the following mutations on an amino acid sequence of IL-2: 1) an insertion of at least one amino acid residue having a smaller side chain between positions T10 ...
|
|
WO/2024/083185A1 |
The application relates to an isolated monoclonal antibody that specifically binds FGFR2B, or an antigen binding portion thereof. The application also relates to a nucleic acid molecule encoding the antibody or antigen binding portion th...
|
|
WO/2024/026505A3 |
The present disclosure is drawn to compositions, combinations of compounds, and methods of treating a cancer or neoplasia, including disrupting activity of telocytes associated with the cancer.
|
|
WO/2024/052563A4 |
The present invention relates to the protein myeloid-derived growth factor (MYDGF) or nucleic acids encoding said protein for use in treating and/or preventing cardiogenic shock. The present invention also relates to vectors comprising t...
|
|
WO/2024/085251A1 |
The purpose of the present invention is to provide a method for evaluating the quality of a retinal implant without actually performing retinal implanting. The present invention relates to a method for evaluating the quality of a retin...
|
|
WO/2024/084518A1 |
The present invention discloses a recombinant nucleic acid molecule encoded at least by an ORF (100, 100a, 100b) to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one hairpin loop str...
|
|
WO/2024/085280A1 |
The present invention relates to a novel kynureninase and a use thereof for cancer treatment. The novel kynureninase demonstrates similar or higher catalytic activity and thermal stability compared to already known kynureninases, and is ...
|
|
WO/2024/085257A1 |
The present invention addresses the problem of providing a three-dimensional tissue culture and a method for producing the same. The problem is solved by this method for producing a three-dimensional tissue culture, the method comprising...
|
